Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wyndham H Wilson

Showing results (1-10 of 217) with videos related to

Pageof 22
Sort By:
The Lancet. Haematology|March 3, 2019
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' replyWyndham H Wilson
Seminars in Hematology|October 10, 2006
Drug resistance in diffuse large B-cell lymphomaWyndham H Wilson
Cytometry. Part B, Clinical Cytometry|September 7, 2007
International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasiaWyndham H Wilson
Hematology. American Society of Hematology. Education Program|December 10, 2013
Treatment strategies for aggressive lymphomas: what works?Wyndham H Wilson
The New England Journal of Medicine|January 28, 2016
Progress in Chronic Lymphocytic Leukemia with Targeted TherapyWyndham H Wilson
Leukemia & Lymphoma|November 12, 2021
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cureChristopher Melani, Wyndham H Wilson
Oncology (Williston Park, N.Y.)|May 21, 2014
Appropriate management of molecular subtypes of diffuse large B-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Best Practice & Research. Clinical Haematology|March 14, 2012
EBV-associated lymphomas in adultsMark Roschewski, Wyndham H Wilson
Leukemia & Lymphoma|August 28, 2010
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategyKieron Dunleavy, Wyndham H Wilson
Pageof 22

Showing results (1-10 of 217) with videos related to

Sort By:
Pageof 22
The Lancet. Haematology|March 3, 2019
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' replyWyndham H Wilson
Seminars in Hematology|October 10, 2006
Drug resistance in diffuse large B-cell lymphomaWyndham H Wilson
Cytometry. Part B, Clinical Cytometry|September 7, 2007
International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasiaWyndham H Wilson
Hematology. American Society of Hematology. Education Program|December 10, 2013
Treatment strategies for aggressive lymphomas: what works?Wyndham H Wilson
The New England Journal of Medicine|January 28, 2016
Progress in Chronic Lymphocytic Leukemia with Targeted TherapyWyndham H Wilson
Leukemia & Lymphoma|November 12, 2021
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cureChristopher Melani, Wyndham H Wilson
Oncology (Williston Park, N.Y.)|May 21, 2014
Appropriate management of molecular subtypes of diffuse large B-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Best Practice & Research. Clinical Haematology|March 14, 2012
EBV-associated lymphomas in adultsMark Roschewski, Wyndham H Wilson
Leukemia & Lymphoma|August 28, 2010
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategyKieron Dunleavy, Wyndham H Wilson
Pageof 22